Myriad Genetics Announces The Incorporation Of Its HRD Platform In Illumina's Updated Gene Panel Assay
Myriad Genetics Announces Incorporation of Its Proprietary HRD Platform in Illumina's Updated Comprehensive Gene Panel Assay, TruSight Oncology 500 V2
If RFK Jr. Cuts Science Funding, These Instrument Makers May Suffer -- Barrons.com
Illumina, Inc. (ILMN) CFO Ankur Dhingra Hosts Wolfe Research 2024 Healthcare Conference (Transcript)
Because Minna announced the expansion of the TruSight Oncology product line.
The latest solution will be unveiled at the annual meeting of the Molecular Pathology Association to achieve a comprehensive mutation analysis of tumors. Research and sharing led by Illumina customers will provide the latest evidence and related content for tumor analysis. San Diego, California, USA, November 20, 2024 / PRNewswire / -- Illumina Inc. (NASDAQ: ILMN), a leader in global DNA sequencing and chip technology, today announced the launch of a new version of its flagship cancer research testing product, TruSight Oncology 500 v2 (TSO 500 v2), for
Express News | Illumina Inc: Trusight Oncology 500 V2 Assay Is Currently Under Development, Global Release Planned for Mid-2025